<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05092217</url>
  </required_header>
  <id_info>
    <org_study_id>rNPC-2021-Dehui Wang</org_study_id>
    <nct_id>NCT05092217</nct_id>
  </id_info>
  <brief_title>Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma</brief_title>
  <official_title>Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma：a Prospecitve, Parallel, Phase II, Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eye &amp; ENT Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eye &amp; ENT Hospital of Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Through open-label, single-center, randomised clinical trials, we intend to demonstrate that&#xD;
      PD-1 treatment added to salvage surgery could further decrease the rate of disease&#xD;
      progression and improve the survival outcome of patients with locally recurrent&#xD;
      nasopharyngeal carcinoma compared with those treated with salvage surgery alone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 20, 2021</start_date>
  <completion_date type="Anticipated">October 20, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 20, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progress-free survival(PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Defined as the time interval from randomization to the observation of disease progression or the occurrence of death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>2 years</time_frame>
    <description>Defined as the time interval from randomization to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional failure-free survival(LRRFS)</measure>
    <time_frame>2 years</time_frame>
    <description>The LRRFS is evaluated and calculated from the date of random assignment until the day of first locoregional relapse or until the date of the last follow-up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis-free survival(DMFS)</measure>
    <time_frame>2 years</time_frame>
    <description>The DMFS is evaluated and calculated from the date of random assignment until the day of first distant metastases or until the date of the last follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment related complications</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of treatment related complications of tirelizumab or surgical treatment during follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Tirelizumab plus salvage surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tirelizumab: Tirelizumab treatment after salvage surgery. Salvage surgery: endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>salvage surgery alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Salvage surgery: endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirelizumab</intervention_name>
    <description>Tirelizumab: 200 mg, intravenous injection over 60 minutes (Q3W); Tirelizumab should be applied since 2-6 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.</description>
    <arm_group_label>Tirelizumab plus salvage surgery</arm_group_label>
    <other_name>PD-1 antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>salvage surgery</intervention_name>
    <description>Endoscopic nasopharyngectomy for recurrent nasopharyngeal tumor</description>
    <arm_group_label>Tirelizumab plus salvage surgery</arm_group_label>
    <arm_group_label>salvage surgery alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed recurrent nasopharyngeal carcinoma&#xD;
&#xD;
          2. The recurrence time is more than 6 months from the end of radiotherapy.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.&#xD;
&#xD;
          4. According to the TNM staging criteria of nasopharyngeal carcinoma (AJCC, 8th Edition,&#xD;
             2017), rT1, rT2, rT3, and rT4 patients who can be completely resected by surgery as&#xD;
             assessed by the surgical team.&#xD;
&#xD;
          5. Resectable recurrent regional lymph node diseases (recurrent N1-3) without&#xD;
             prevertebral fascia, cervical vertebrae, or common/internal carotid artery&#xD;
             involvement.&#xD;
&#xD;
          6. Given written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has severe medical disorder, important organ dysfunction, and/or a substantial history&#xD;
             of mental illness.&#xD;
&#xD;
          2. Has known subjects with other malignant tumors.&#xD;
&#xD;
          3. Has participated in other drug trials within 3 months of planned start of study&#xD;
             treatment.&#xD;
&#xD;
          4. Received a systematic or local glucocorticoid therapy within 4 weeks of planned start&#xD;
             of study treatment.&#xD;
&#xD;
          5. Suffered from diseases need long-term treatment with immunosuppressive drugs, or&#xD;
             required systematic or local glucocorticoid therapy with immunosuppressive doses.&#xD;
&#xD;
          6. Prior therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) or cytotoxic T&#xD;
             lymphocyte-associated antigen 4 (CTLA-4) agent.&#xD;
&#xD;
          7. Has active autoimmune disease (e.g., uveitis, enteritis, hepatitis, hypophysitis,&#xD;
             nephritis, vasculitis, hyperthyroidism, and asthma requiring bronchodilator therapy).&#xD;
             Patients with skin disease that doesn't require systemic treatment (e.g., vitiligo,&#xD;
             psoriasis, or alopecia) will be allowed to enroll.&#xD;
&#xD;
          8. Has a known history of human immunodeficiency virus (HIV), has hepatitis B surface&#xD;
             antigen (HBsAg) positive with hepatitis B virus (HBV) DNA copy number of ≥1000cps/ml&#xD;
             or hepatitis C virus (HCV) antibody positive.&#xD;
&#xD;
          9. Has received a live vaccine within 4 weeks of planned start of study treatment.&#xD;
&#xD;
         10. Pregnancy or breast feeding.&#xD;
&#xD;
         11. Cannot complete regular follow-up.&#xD;
&#xD;
         12. Local recurrence of nasopharyngeal carcinoma with distant metastasis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wanpeng Li, MD</last_name>
    <phone>13262856870</phone>
    <email>18879117831@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li Hu, MD</last_name>
    <phone>18917786049</phone>
    <email>hl318ent@163.com</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 12, 2021</study_first_submitted>
  <study_first_submitted_qc>October 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eye &amp; ENT Hospital of Fudan University</investigator_affiliation>
    <investigator_full_name>Dehui Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Recurrent Nasopharyngeal Carcinoma</keyword>
  <keyword>Tirelizumab</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Endoscopic surgery</keyword>
  <keyword>Survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

